background
serratia
marcescen
import
nosocomi
pathogen
characterist
properti
resist
confer
extendedspectrum
betalactamas
novel
ampc
cephalosporinas
unusu
taiwan
studi
investig
trend
antimicrobi
resist
marcescen
nationwid
surveil
taiwan
materi
method
marcescen
isol
collect
biennial
medic
center
region
hospit
throughout
taiwan
part
taiwan
surveil
antimicrobi
resist
program
minim
inhibitori
concentr
determin
clinic
laboratori
standard
institut
refer
broth
microdilut
method
result
total
nondupl
marcescen
isol
collect
mostli
respiratori
sampl
follow
urinari
tract
sampl
overal
isol
suscept
imipenem
ceftazidim
minocyclin
amikacin
cefepim
aztreonam
ceftriaxon
levofloxacin
ciprofloxacin
trimethoprimsulfamethoxazol
tmpsmx
gentamicin
significantli
increas
suscept
rate
observ
follow
antibiot
amikacin
vs
gentamicin
vs
ciprofloxacin
journal
microbiolog
immunolog
infect
vs
ceftriaxon
vs
cefepim
vs
aztreonam
vs
tmpsmx
vs
conclus
studi
suscept
marcescen
ceftazidim
imipenem
remain
consist
high
taiwan
marcescen
isol
demonstr
rel
higher
resist
ciprofloxacin
levofloxacin
therefor
continu
surveil
antimicrobi
resist
especi
fluoroquinolon
warrant
serratia
speci
identifi
aerob
motil
gramneg
rod
occupi
variou
habitat
mainli
water
plant
soil
human
infect
member
genu
serratia
well
recogn
latter
half
th
centuri
serratia
marcescen
account
major
isol
appear
pathogen
capabl
caus
wide
spectrum
clinic
diseas
includ
wound
infect
urinari
tract
infect
pneumonia
central
nervou
system
infect
mening
bloodstream
infect
although
marcescen
rare
caus
communityacquir
infect
emerg
import
nosocomi
pathogen
cultur
varieti
sourc
includ
disinfect
pressur
transduc
bronchoscop
multidos
medic
vial
factor
debilit
clinic
condit
lengthi
ward
stay
exposur
medic
intervent
increas
frequenc
intens
direct
contact
staff
hand
predispos
patient
marcescen
infect
marcescen
isol
account
nosocomi
urinari
tract
infect
result
fatal
singl
institut
taiwan
although
marcescen
rel
low
virul
often
caus
nosocomi
infect
sever
immunocompromis
critic
ill
patient
mortal
rate
marcescen
bacteremia
approxim
previou
studi
marcescen
usual
resist
ampicillin
amoxicillin
amoxicillinclavulan
ampicillinsulbactam
narrowspectrum
cephalosporin
cefuroxim
cephamycin
nitrofurantoin
colistin
marcescen
also
harbor
chromosom
ampc
gene
extend
resist
sever
blactam
antibiot
nationwid
surveil
antimicrobi
resist
taiwan
half
marcescen
resist
ciprofloxacin
resist
cefotaxim
aztreonam
cefepim
respect
howev
mani
studi
recent
year
suggest
occurr
extendedspectrum
betalactamas
esbl
produc
isol
marcescen
unusu
taiwan
addit
institut
prolong
spread
clonal
relat
marcescen
isol
novel
ampc
cephalosporinas
confer
phenotyp
resist
cefotaxim
identifi
therefor
continu
extens
surveil
antimicrobi
resist
among
marcescen
isol
necessari
taiwan
aim
studi
investig
trend
antimicrobi
resist
marcescen
nationwid
surveil
taiwan
isol
collect
identif
marcescen
isol
collect
biennial
correspond
period
iiievii
taiwan
surveil
antimicrobi
resist
tsar
program
medic
center
region
hospit
throughout
taiwan
collect
juli
septemb
hospit
except
isol
hospit
hospit
compris
medic
center
region
hospit
locat
four
region
taiwan
name
seven
eight
eight
three
hospit
north
central
south
east
region
respect
detail
collect
process
tsar
program
describ
previous
isol
subcultur
onto
appropri
agar
plate
bbl
becton
dickinson
microbiolog
system
cockeysvil
md
usa
check
puriti
marcescen
identifi
standard
convent
biochem
test
follow
confirm
vitek
gramneg
identif
plu
card
vitek
hazelwood
mo
usa
analyt
profil
index
api
api
marcyletoil
franc
antimicrobi
suscept
determin
refer
broth
microdilut
method
use
freshli
prepar
cationadjust
broth
follow
criteria
propos
clinic
laboratori
standard
institut
clsi
minimum
inhibitori
concentr
mic
interpret
criteria
defin
clsi
guidelin
drug
except
tigecyclin
us
food
drug
administr
breakpoint
use
analys
perform
spss
version
spss
inc
chicago
il
usa
signific
differ
frequenc
proport
test
pearson
c
test
p
consid
static
signific
total
nondupl
marcescen
isol
identifi
test
suscept
studi
period
tabl
summar
sourc
breakdown
isol
run
tsar
isol
mostli
recov
respiratori
sampl
isol
follow
urinari
tract
blood
isol
inpati
includ
intens
care
unit
icu
nonicu
patient
isol
northern
taiwan
compris
largest
proport
among
isol
whose
patient
age
known
mean
age
ae
year
age
year
vitro
suscept
mic
mic
mic
isol
inhibit
mic
rang
isol
variou
antimicrobi
agent
shown
tabl
overal
isol
suscept
imipenem
ceftazidim
piperacillin
tazobactam
levofloxacin
ciprofloxacin
trimethoprimsulfamethoxazol
tmpsmx
gentamicin
accord
clsi
criteria
contrast
suscept
round
tsar
observ
ampicillin
amoxicillinclavulan
cefazolin
cefoxitin
cefuroxim
tetracyclin
mic
mic
tigecyclin
mgml
mgml
respect
suscept
rate
marcescen
differ
patient
locat
compar
tabl
isol
icu
higher
rate
nonsuscept
isol
locat
amikacin
gentamicin
ciprofloxacin
levofloxacin
ceftazidim
cefepim
tmpsmx
differ
signific
suscept
rate
ciprofloxacinlevofloxacin
lower
northern
taiwan
region
p
z
p
z
respect
fig
illustr
comparison
suscept
rate
select
antibiot
differ
specimen
sourc
found
isol
urin
lowest
suscept
rate
variou
antibiot
isol
urin
significantli
less
suscept
nonurin
sourc
amikacin
other
one
ascit
one
joint
two
bile
four
ear
seven
cathet
tip
four
eyesconjunctiva
cornea
one
urethra
one
discharg
b
includ
six
isol
respiratori
care
centerrespiratori
care
ward
er
z
emerg
room
icu
z
intens
care
unit
opd
z
outpati
depart
tsar
z
taiwan
surveil
antimicrobi
resist
program
data
present
n
present
studi
examin
trend
suscept
multipl
antibiot
nondupl
clinic
marcescen
isol
taiwan
result
show
activ
ceftazidim
imipenem
remain
consist
high
year
suscept
round
tsar
observ
ampicillin
amoxicillinclavulan
cefazolin
cefoxitin
cefuroxim
tetracyclin
fluoroquinolon
show
less
activ
marcescen
blactam
taiwan
occurr
esblproduc
isol
marcescen
unusu
novel
ampc
cephalosporinas
report
previous
distinct
properti
resist
cefotaxim
ceftazidim
due
esbl
srtlike
ampc
confer
phenotyp
resist
cefotaxim
antibiogrambas
method
simplifi
screen
potenti
esblproduc
popul
among
marcescen
isol
also
report
recent
although
molecular
characterist
isol
lack
current
studi
higher
suscept
ceftazidim
ceftriaxon
correspond
previou
studi
underlin
need
establish
practic
guidelin
esbl
screen
confirm
report
chromosom
ampc
produc
taiwan
tigecyclin
evalu
surveil
trial
studi
isol
marcescen
collect
global
suscept
observ
amikacin
levofloxacin
ceftazidim
cefepim
imipenem
meropenem
piperacillintazobactam
tigecyclin
similar
studi
conduct
hawser
et
al
collect
clinic
isol
marcescen
throughout
asiaepacif
region
demonstr
constantli
high
suscept
levofloxacin
characterist
find
present
studi
much
lower
suscept
levofloxacin
ceftriaxon
compar
global
data
suscept
levofloxacin
current
studi
test
suscept
ciprofloxacin
test
throughout
studi
period
much
lower
suscept
ciprofloxacin
suggest
resist
fluoroquinolon
major
concern
surround
drugresist
marcescen
taiwan
suscept
rate
ceftriaxon
asiaepacif
region
consist
find
hawser
et
al
also
demonstr
declin
suscept
minocyclin
decreas
tigecyclin
marcescen
contrast
suscept
minocyclin
tigecyclin
test
present
studi
show
higher
suscept
rate
respect
shih
et
al
found
marcescen
blood
isol
sensit
ceftazidim
sensit
ciprofloxacin
levofloxacin
tmpsmx
singl
institut
taiwan
high
suscept
rate
ceftazidim
consist
current
studi
previou
nationwid
surveil
antimicrobi
resist
among
enterobacteriacea
icu
major
teach
hospit
taiwan
report
low
suscept
marcescen
ciprofloxacin
levofloxacin
present
studi
show
increas
suscept
ciprofloxacin
levofloxacin
compar
previou
result
taiwan
resist
fluoroquinolon
continu
problem
taiwan
examin
trend
antimicrobi
suscept
reveal
higher
resist
rate
amikacin
gentamicin
ciprofloxacin
ceftriaxon
cefepim
aztreonam
tmp
smx
prior
date
higher
proport
isol
recov
urin
may
influenc
result
significantli
higher
proport
isol
recov
urin
p
may
influenc
result
reason
isol
urin
lowest
suscept
rate
variou
antibiot
clearli
defin
might
impli
put
focu
resist
pattern
urinari
isol
addit
emerg
sever
acut
respiratori
syndrom
reinforc
prevent
health
careassoci
infect
hospit
result
cautiou
approach
intervent
antimicrobi
part
infect
control
polici
trend
total
consumpt
aminoglycosid
extendedspectrum
cephalosporin
fluoroquinolon
significantli
increas
prior
remain
stabl
hospitalwid
investig
reduc
consumpt
antibiot
taiwan
may
explain
observ
greater
suscept
present
studi
recogn
number
potenti
bias
present
studi
first
limit
concern
specimen
type
isol
urinari
tract
show
higher
resist
rate
mani
antibiot
site
therefor
higher
percentag
urin
specimen
prior
may
result
lower
overal
suscept
period
second
isol
collect
eastern
taiwan
data
like
underestim
event
occur
region
third
analyz
resist
mechan
due
lack
molecular
method
multiplex
polymeras
chain
reaction
screen
ampc
gene
marcescen
isol
final
given
limit
clinic
inform
surveil
exactli
determin
clinic
signific
isol
conclus
result
studi
suggest
suscept
marcescen
ceftazidim
imipenem
taiwan
remain
consist
high
studi
period
marcescen
isol
taiwan
demonstr
rel
higher
resist
ciprofloxacin
levofloxacin
blactam
continu
surveil
antimicrobi
resist
marcescen
especi
fluoroquinolon
warrant
tsar
ongo
taiwan
involv
clinic
import
bacteria
longitudin
surveil
studi
continu
provid
key
inform
relat
antimicrobi
resist
time
author
declar
conflict
interest
